Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Garp1on May 20, 2023 9:08am
171 Views
Post# 35457632

RE:RE:RE:RE:RE:RE:What's next and when

RE:RE:RE:RE:RE:RE:What's next and when
I have concerns about your point of view SPCEO1. I believe the primary focus for Thera's success should be the improvement and maximization of sales for its approved products, and that Paul was hired for his expertise in marketing and sales to achieve this goal. I also acknowledge the strategic importance of developing new products for future growth and diversification, but I maintain that it should not come at the expense of the company's stability and sales performance.
I expect Paul to be aware of the need to prioritize the current products, ensure their success, and communicate to stakeholders the security of their investment. If TH-1902 were to succeed, I agree that a CEO with marketing and sales experience would become even more crucial for effectively bringing the third product to market.
I do not believe that Thera has already maximized the potential of its current products trough the CEO and the board of directors should have reassessed the situation and taken action either to improve marketing, sales and communication. Insofar as product development is concerned, I do not see Paul as the best candidate to pursue this endeavor without significant cost associated to his apprenticeship and the board should have recognise this.
<< Previous
Bullboard Posts
Next >>